- Home
- ADXN vs ICU Comparison
ADXN vs ICU Comparison
Compare ADXN & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADXN | ICU |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 9.1M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | ADXN | ICU |
|---|---|---|
| Price | $7.00 | $3.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.5K | ★ 241.5K |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $86.57 | $93.92 |
| Revenue Next Year | N/A | $39.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.41 | $0.22 |
| 52 Week High | $12.05 | $4.93 |
Technical Indicators
Market Signals| Indicator | ADXN | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 49.63 | 59.87 |
| Support Level | $5.57 | $2.26 |
| Resistance Level | $8.60 | N/A |
| Average True Range (ATR) | 0.59 | 0.50 |
| MACD | 0.10 | 0.09 |
| Stochastic Oscillator | 59.80 | 58.39 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.